Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil Liposome for Injection in Healthy Adult Volunteers
NCT02889822Phase 1Completed
- Sponsor
- ApicHope Pharmaceutical Group
- Start
- Mar 2010
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Alprostadil Liposomes for Injection in peripheral arterial occlusive disease (PAOD) (2 arms), sponsored by ApicHope Pharmaceutical Group. Primary endpoint: Safety assessment of Alprostadil Liposome for Injection at 14 days. Started Mar 2010; status: completed.
02
Drugs
Alprostadil Liposomes for Injection
03
Conditions
peripheral arterial occlusive disease (PAOD)
Beyond the preview
Go deeper on NCT02889822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889822.